PhaseBio Pharmaceuticals Gross Profit

PhaseBio Pharmaceuticals (PHAS) currently reports a gross profit of $820K as of June 2022. That compares with $11M in the prior-year period — down 92.3% year over year. That is below the Healthcare sector average of $64B. Use the charts on this page to explore PhaseBio Pharmaceuticals's gross profit history and peer comparisons.

PhaseBio Pharmaceuticals's gross profit decreased from $11M to $820K — a 92.3% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PhaseBio Pharmaceuticals's gross profit of $820K is lower than the Healthcare sector average of $64B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

PhaseBio Pharmaceuticals reported $820K in gross profit as of June 2022. That compares with $11M in the prior-year period — down 92.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $820K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $64B. From there, open related valuation or income-statement pages for PhaseBio Pharmaceuticals, and consider following PHAS for alerts when major investors trade the stock.